Prognostic Role of Pre-Treatment Carcinoembryonic Antigen and Carbonhydrate Antigen 19-9 in Metastatic Colorectal Cancer
Semiha Urvay1, Hatice Karagoz21Department of Medical Oncology, Acibadem University Vocational School of Health Services, Radiotherapy, Istanbul Acibadem Kayseri Hospital, Kayseri, Turkey Department of Medical Oncology, Acibadem University Vocational School of Health Services, Radiotherapy, Istanbul Acibadem Kayseri Hospital, Kayseri, Turkey, 2Department of Internal Medicine, Acibadem Kayseri Hospital, Kayseri, Turkey
Objectives: Carcinoembrionic Antigen (CEA) and carbohydrateantigen 19-9 (CA 19-9) are the most commonly used tumor-associated antigens in the colorectal cancer. Several contradictory studies reported that patients with metastatic colorectal cancer (mCRC) with normal serum CEA and CA 19-9 levels survived significantly longer than patients with higher serum CEA and CA19-9 levels. Methods: 240 patients with mCRC were enrolled. The parameters evaluated were age, gender, tumor location, metastatic organs, resection of the primary tumor, metastasectomy, pretreatment serum concentrations of CEA and CA19-9, first line chemotherapy regimens and overall survival (OS). CEA and CA19-9 were divided into three groups as normal (CEA ?5 ng/mL, CA 19-9 ?35 U/mL) elavated (CEA: 5–50 ng/mL, CA19-9:35–350 U/mL) and high (CEA >50 ng/mL, and CA 19-9 >350 U/mL). Primary study endpoint was overall survival (OS). Results: Serum CA 19-9 level (p=0.040), primary tumor resection (p<0.001), metastasectomy (p=0.042) and tumor location (p=0.029) were independent predictors of survival in multivariate analysis. The survival was 29.5, 21.2 and 15.4 months for the patients with normal, elevated and high CA 19-9 levels. Conclusion: High pretreatment serum CA19-9 may be a useful predictive factor of survival rather then CEA in patients with stage IV CRC. Keywords: Carbohydrate antigen (CA) 19-9, carcinoembryonic antigen, metastatic colorectal cancer, survival
Cite This Article
Urvay S, Karagoz H. Prognostic Role of Pre-Treatment Carcinoembryonic Antigen and Carbonhydrate Antigen 19-9 in Metastatic Colorectal Cancer. EJMI. 2021; 5(1): 73-80
Corresponding Author: Semiha Urvay